Previous 10 | Next 10 |
Summary Children suffering dystrophic epidermolysis bullosa (DEB), a serious genetic disease, are affectionately called butterfly children, depicting their fragile, recurrent blistering skin with chronic open wounds. Currently, there are three potential DEB treatments that have co...
Abeona Therapeutics ( NASDAQ: ABEO ) on Thursday said a phase 3 trial of its cell therapy EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) met its main goals. RDEB is a rare connective tissue disorder characterized by severe skin wounds tha...
Abeona Therapeutics ( NASDAQ: ABEO ) on Thursday announced $35M private placement financing . The company will sell ~7.1M shares, pre-funded warrants exercisable for 543.9K shares (in lieu of shares), and accompanying warrants to purchase 7.6M shares to a group of new and ...
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded warrants exercisable fo...
Co-primary endpoint measuring > 50% wound healing, other endpoints measuring > 75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was o...
Summary Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 mi...
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive...
Cheap Penny Stocks To Buy Penny stocks generally trade for $5 per share, which makes them some of the most appealing for new or novice traders. The ability to purchase hundreds, thousands, or even millions of shares for a couple of hundred dollars gives way to scoring big when stocks ex...
If you’re looking for the best penny stocks to buy, you likely understand the disconnect between broader trends and cheap stocks. Since penny stocks move independently, most of the time, you’re sure to find at least a few companies to follow. Today this became more evi...
Shares of Abeona Therapeutics ( NASDAQ: ABEO ) gained 10.4% to $3.62 in Tuesday mid-day trading, extending a recent strong run which has seen the stock post gains in four of its last five sessions . The stock rose 7.9% yesterday after Cantor Fitzgerald listed...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...